Prednicarbate
(Synonyms: 泼尼卡酯) 目录号 : GC44677
A synthetic corticosteroid
Cas No.:73771-04-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Prednicarbate is a synthetic corticosteroid and a derivative of prednisolone . It has anti-inflammatory activity comparable to that of desoximetasone in various murine models when administered topically but lacks activity when administered subcutaneously. Topical administration of prednicarbate (2 drops of a 0.1% solution per day) induces wound healing in hairless mice. Formulations containing prednicarbate have been used to treat chronic hand eczema.
| Cas No. | 73771-04-7 | SDF | |
| 别名 | 泼尼卡酯 | ||
| Canonical SMILES | [H][C@]12[C@@]([C@@](CC[C@]3(OC(OCC)=O)C(COC(CC)=O)=O)([H])[C@]3(C)C[C@@H]2O)([H])CCC4=CC(C=C[C@@]41C)=O | ||
| 分子式 | C27H36O8 | 分子量 | 488.6 |
| 溶解度 | Chloroform: Slightly Soluble,Ethanol: Slightly Soluble,Methanol: Slightly Soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0467 mL | 10.2333 mL | 20.4666 mL |
| 5 mM | 0.4093 mL | 2.0467 mL | 4.0933 mL |
| 10 mM | 0.2047 mL | 1.0233 mL | 2.0467 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Prednicarbate (Dermatop): profile of a corticosteroid
J Cutan Med Surg 2004 Jul-Aug;8(4):244-7.PMID:16092003DOI:10.1007/s10227-004-0120-x.
Background: Topical steroids have been a popular choice for treating various cutaneous disorders; however, the potential for significant local and systemic adverse events, like skin atrophy and hypothalamic-pituitary-adrenal (HPA) axis suppression, has limited their use. Objective: This article reviews the topical steroid Prednicarbate through its mechanism of action, clinical efficacy, and adverse events profile. Methods: Published literature containing the word "Prednicarbate" was examined and summarized. Results: Prednicarbate is a nonhalogenated, double-ester derivative of prednisolone that has been used in the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as atopic dermatitis. It has a favorable benefit-risk ratio, low skin atrophy potential, and high anti-inflammatory action. Conclusion: These characteristics make Prednicarbate an ideal alternative agent for children, elderly patients, and those who require long-term intermittent treatment.
A review of Prednicarbate (Dermatop)
Skin Therapy Lett 2004;9(10):5-6, 9.PMID:15657633doi
Prednicarbate is a nonhalogenated corticosteroid that is used in the treatment of inflammatory skin diseases, for example atopic dermatitis. It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy. Thus, Prednicarbate may be a consideration in the treatment of atopic dermatitis in children, and other inflammatory disorders in children and adults.
Prednicarbate (dermatop): a review
J Drugs Dermatol 2004 Sep-Oct;3(5):553-6.PMID:15552608doi
Prednicarbate is a non-halogenated, double-ester derivative of prednisolone that has become of interest for the treatment of inflammatory skin diseases, for example atopic dermatitis. In the past, topical steroids have been a popular choice for treating these diseases; however, the potential for significant local and systemic adverse events, such as skin atrophy and hypothalamic-pituitary-adrenal (HPA) axis suppression have limited their use. Prednicarbate has been found to have a favorable benefit-risk ratio, with low skin atrophy potential, and a high anti-inflammatory action. Prednicarbate may be particularly advantageous when used intermittently in pediatric and elderly patients.
Prednicarbate: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders
BioDrugs 1998 Jan;9(1):61-86.PMID:18020557DOI:10.2165/00063030-199809010-00006.
Prednicarbate is a synthetic nonhalogenated moderate to high potency corticosteroid. It is rapidly metabolised during skin permeation to prednisolone. Prednicarbate is indicated for relief of inflammation and pruritus associated with corticosteroid-responsive dermatological disorders such as dermatitis (eczema) [including atopic dermatitis] and psoriasis and can be used in children and elderly patients. Large clinical trials conducted in patients with various dermatoses confirm the efficacy of the drug. Smaller trials, conducted in patients with dermatitis, show Prednicarbate generally to have similar activity to comparator corticosteroids. Data concerning use of Prednicarbate in psoriasis are more limited, although again the drug demonstrated similar efficacy to the corticosteroids with which it was compared. The tolerability of Prednicarbate was generally good, although methods of recording adverse events were not clearly reported in many trials. The atrophogenic potential of Prednicarbate appears to be low when no occlusion is used. However, atrophogenic effects increase with occlusion. Therefore, Prednicarbate is a useful option for the treatment of corticosteroid-responsive dermatoses and appears to have low atrophogenic potential when used without occlusion.
Prednicarbate versus fluocortin for inflammatory dermatoses. A cost-effectiveness study
Pharmacoeconomics 1997 Aug;12(2 Pt 1):193-208.PMID:10169671DOI:10.2165/00019053-199712020-00009.
The purpose of this study was to compare, from a societal perspective, the cost effectiveness of topical Prednicarbate 0.25% and fluocortin 0.75% in the treatment of inflammatory dermatoses, such as dermatitis and eczema, in Spain. Effectiveness and tolerability were determined by means of a meta-analysis of 17 randomised double-blind controlled clinical trials, using a MEDLINE search and a second-level reference search. The data were obtained on the basis of a per-protocol assessment system, and the Mantel-Haenszel method (as modified by Peto) was used to make the statistical analysis. In terms of economic assessment, a model was developed in which the expected total cost was determined by the cost of the medicine (adjusted to the recommended dosage) plus the costs derived from the ineffectiveness and/or adverse effects associated with the different treatments. A sensitivity analysis was carried out on the basis of changes in: (i) clinical effectiveness; (ii) price of Prednicarbate; (iii) incidence of adverse reactions; (iv) costs associated with ineffectiveness and/or adverse effects; and (v) the regimen under which Prednicarbate was administered. The meta-analysis showed that there was a statistically significant difference between the 2 alternatives (p = 0.001). The value of a combined odds ratio [and 95% confidence interval (95% CI)] for the combined studies of Prednicarbate was 1.54 (95% CI 1.10 to 2.15), compared with 0.73 (95% CI 0.60 to 0.89) for fluocortin relative to moderate or moderate-to-high potency corticosteroids. Effectiveness was 84.9% for Prednicarbate and 69.7% for fluocortin, while frequency of adverse effects was 3.5% for Prednicarbate and 4.9% for fluocortin. The total expected cost per patient treated was found to be 4600 Spanish pesetas (Pta) [$US37.10; 1996 values] for Prednicarbate and Pta5778 ($US46.60; 1996 values) for fluocortin. The total expected cost per patient successfully treated was Pta5608 ($US45.20) for Prednicarbate and Pta8680 ($US70) for fluocortin. Prednicarbate has been shown to have a favourable cost-effectiveness ratio, when compared with fluocortin, for the treatment of dermatitis and eczema in Spain. Additional pharmacoeconomic studies on topical corticosteroids are required, including the use of new variables, long term analysis and/or the measurements of the effect of the drug on patients' quality of life.